A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.
A panel of cytolytic T lymphocyte (CTL) clones was isolated from metastases and blood samples of a melanoma patient vaccinated with MAGE-3.A1-pulsed autologous dendritic cells. We report here the identification of a new antigen encoded by the MAGE-C2 cancer-germline gene. This antigen is recognized by some of these CTL on HLA-B*4403. The sequence of the peptide is SESIKKKVL. It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403. Because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific and could therefore be used for peptide-based antitumoral vaccination.
Godelaine
Danièle
D
Ludwig Institute for Cancer Research, 74 avenue Hippocrate, UCL 7459, 1200 Brussels, Belgium.
Carrasco
Javier
J
Brasseur
Francis
F
Neyns
Bart
B
Thielemans
Kris
K
Boon
Thierry
T
Van Pel
Aline
A
D000595:Amino Acid Sequence; D000818:Animals; D017951:Antigen Presentation / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000235:genetics* / Q000276:immunology; D019556:COS Cells; D019496:Cancer Vaccines / Q000627:therapeutic use; D002522:Chlorocebus aethiops; D002999:Clone Cells; D003713:Dendritic Cells / Q000637:transplantation; D015235:HLA-B Antigens / Q000276:immunology*; D059948:HLA-B44 Antigen; D006801:Humans; D008545:Melanoma / Q000628:therapy; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014162:Transfection
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D015235:HLA-B Antigens; D059948:HLA-B44 Antigen; C405429:MAGEC2 protein, human; D009363:Neoplasm Proteins